vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Federal Realty Investment Trust (FRT). Click either name above to swap in a different company.
Federal Realty Investment Trust is the larger business by last-quarter revenue ($336.0M vs $263.6M, roughly 1.3× BALCHEM CORP). Federal Realty Investment Trust runs the higher net margin — 38.6% vs 14.9%, a 23.7% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (9.8% vs 8.7%). Over the past eight quarters, Federal Realty Investment Trust's revenue compounded faster (6.5% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
BCPC vs FRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $336.0M |
| Net Profit | $39.2M | $129.7M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | 53.8% |
| Net Margin | 14.9% | 38.6% |
| Revenue YoY | 9.8% | 8.7% |
| Net Profit YoY | 16.8% | 103.5% |
| EPS (diluted) | $1.21 | $1.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $336.0M | ||
| Q4 25 | $263.6M | $336.0M | ||
| Q3 25 | $267.6M | $322.3M | ||
| Q2 25 | $255.5M | $311.5M | ||
| Q1 25 | $250.5M | $309.2M | ||
| Q4 24 | $240.0M | $311.4M | ||
| Q3 24 | $239.9M | $303.6M | ||
| Q2 24 | $234.1M | $296.1M |
| Q1 26 | — | $129.7M | ||
| Q4 25 | $39.2M | $129.7M | ||
| Q3 25 | $40.3M | $61.6M | ||
| Q2 25 | $38.3M | $155.9M | ||
| Q1 25 | $37.1M | $63.8M | ||
| Q4 24 | $33.6M | $65.5M | ||
| Q3 24 | $33.8M | $61.0M | ||
| Q2 24 | $32.1M | $112.0M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | — | 53.8% | ||
| Q4 25 | 19.8% | 53.8% | ||
| Q3 25 | 20.4% | 34.3% | ||
| Q2 25 | 20.1% | 65.1% | ||
| Q1 25 | 20.4% | 35.0% | ||
| Q4 24 | 19.8% | 35.1% | ||
| Q3 24 | 20.0% | 34.9% | ||
| Q2 24 | 19.6% | 53.0% |
| Q1 26 | — | 38.6% | ||
| Q4 25 | 14.9% | 38.6% | ||
| Q3 25 | 15.1% | 19.1% | ||
| Q2 25 | 15.0% | 50.0% | ||
| Q1 25 | 14.8% | 20.6% | ||
| Q4 24 | 14.0% | 21.0% | ||
| Q3 24 | 14.1% | 20.1% | ||
| Q2 24 | 13.7% | 37.8% |
| Q1 26 | — | $1.49 | ||
| Q4 25 | $1.21 | $1.49 | ||
| Q3 25 | $1.24 | $0.69 | ||
| Q2 25 | $1.17 | $1.78 | ||
| Q1 25 | $1.13 | $0.72 | ||
| Q4 24 | $1.03 | $0.74 | ||
| Q3 24 | $1.03 | $0.70 | ||
| Q2 24 | $0.98 | $1.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $107.4M |
| Total DebtLower is stronger | — | $5.0B |
| Stockholders' EquityBook value | $1.3B | $3.2B |
| Total Assets | $1.7B | $9.1B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $107.4M | ||
| Q4 25 | $74.6M | $107.4M | ||
| Q3 25 | $65.1M | $111.3M | ||
| Q2 25 | $65.4M | $177.0M | ||
| Q1 25 | $49.9M | $109.2M | ||
| Q4 24 | $49.5M | $123.4M | ||
| Q3 24 | $73.7M | $97.0M | ||
| Q2 24 | $63.7M | $103.2M |
| Q1 26 | — | $5.0B | ||
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.3B | $3.2B | ||
| Q3 25 | $1.3B | $3.2B | ||
| Q2 25 | $1.3B | $3.2B | ||
| Q1 25 | $1.2B | $3.2B | ||
| Q4 24 | $1.1B | $3.2B | ||
| Q3 24 | $1.2B | $3.1B | ||
| Q2 24 | $1.1B | $3.0B |
| Q1 26 | — | $9.1B | ||
| Q4 25 | $1.7B | $9.1B | ||
| Q3 25 | $1.7B | $8.9B | ||
| Q2 25 | $1.7B | $8.6B | ||
| Q1 25 | $1.6B | $8.6B | ||
| Q4 24 | $1.6B | $8.5B | ||
| Q3 24 | $1.6B | $8.5B | ||
| Q2 24 | $1.6B | $8.4B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.42× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $67.3M | $622.4M | ||
| Q3 25 | $65.6M | $147.8M | ||
| Q2 25 | $47.3M | $150.7M | ||
| Q1 25 | $36.5M | $179.0M | ||
| Q4 24 | $52.3M | $574.6M | ||
| Q3 24 | $51.3M | $144.1M | ||
| Q2 24 | $45.0M | $169.7M |
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | 4.80× | ||
| Q3 25 | 1.63× | 2.40× | ||
| Q2 25 | 1.23× | 0.97× | ||
| Q1 25 | 0.98× | 2.81× | ||
| Q4 24 | 1.56× | 8.77× | ||
| Q3 24 | 1.52× | 2.36× | ||
| Q2 24 | 1.40× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
FRT
Segment breakdown not available.
